REG - GSK PLC - Board and Committee Changes

GSKAnnouncement

22/07/2022 16:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220722:nRSV5056Ta&default-theme=true

RNS Number : 5056T  GSK PLC  22 July 2022

Issued: 22 July 2022, London UK

 

Board and Committee changes

 

 

 

 

GSK plc (LSE/NYSE: GSK) has today announced the following changes to its Board
and Committees, which took effect immediately following the demerger of the
Consumer Healthcare business on Monday 18 July 2022 (the Demerger):

 

 ·                             Charles Bancroft has succeeded Vindi Banga as Senior Independent Non-Executive
                               Director. Mr Bancroft has also been appointed a member of the Remuneration
                               Committee.

 ·                             Urs Rohner has been appointed a member of the Audit & Risk Committee.

 ·                             Dr Anne Beal has been appointed a member of the Remuneration and Nominations
                               & Corporate Governance committees.

 ·                             Dr Vishal Sikka who joined the Board on 18 July 2022 has been appointed a
                               member of the Corporate Responsibility Committee. In addition, Dr Sikka will
                               attend Audit & Risk Committee meetings to support the Committee's
                               oversight of GSK's Digital and Technology programme.

The Board has determined that given the refreshment of the Board following the
Demerger and the Company's renewed focus the whole Board will engage with the
workforce to gather employees' perspectives rather than designating a specific
Non-Executive Director for this purpose. A programme of events is in place to
facilitate engagement with employees to gather and understand directly their
views.

 

As previously announced:

 

 ·                         Vindi Banga and Dame Vivienne Cox stepped down from the GSK Board upon their
                           appointments to the Haleon plc Board effective on Demerger.

 ·                         Lynn Elsenhans retired from the Board effective from the Demerger.

 

These changes continue the transition of the Board as an independent biopharma
company post separation. GSK expects to announce further Non-Executive
Director appointments shortly.

 

Board and Committee Membership with effect from 18 July 2022:

 

 Board Membership

 Sir Jonathan Symonds  Non-Executive Chair

 Emma Walmsley         Chief Executive Officer

 Iain Mackay           Chief Financial Officer

 Dr Hal Barron*        Chief Scientific Officer

 Charles Bancroft      Senior Independent Non-Executive Director

 Dr Anne Beal          Independent Non-Executive Director

 Dr Hal Dietz          Independent Non-Executive Director

 Dr Laurie Glimcher    Independent Non-Executive Director

 Dr Jesse Goodman      Independent Non-Executive Director

 Urs Rohner            Independent Non-Executive Director

 Dr Vishal Sikka       Independent Non-Executive Director

*Dr Barron will transition to a Non-Independent Non-Executive Director with
effect from 1 August 2022.

 

 

 

 

 Board Committee                                   Committee Chair       Members
 Audit & Risk Committee                            Charles Bancroft*     Dr Anne Beal

                                                                         Dr Laurie Glimcher

                                                                         Urs Rohner

 Remuneration Committee                            Urs Rohner            Charles Bancroft

                                                                         Dr Anne Beal

 Nominations & Corporate Governance Committee      Sir Jonathan Symonds  Charles Bancroft

                                                                         Dr Anne Beal

                                                                         Urs Rohner

 Corporate Responsibility Committee                Dr Anne Beal          Dr Jesse Goodman

                                                                         Dr Vishal Sikka

 Science Committee                                 Dr Jesse Goodman**    Dr Hal Dietz**

                                                                         Dr Laurie Glimcher**

                                                                         Dr Hal Barron (wef 1 August 2022)

 Chairs' Committee                                 Sir Jonathan Symonds  Senior Independent Non-Executive Director

                                                                         Chairs of the Board's Committees

*   Audit committee financial expert

** Scientific and Medical Expert

 

Victoria Whyte

Company Secretary

22 July 2022

 

 

Notes

 

 A.       The following information is available for reference on
 www.GSK.com:

 1.   Biographies of each Board member            Board of directors and leadership team | GSK
                                                  (https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/)
 2.   Terms of reference of each Board Committee  Committees | GSK (https://www.gsk.com/en-gb/company/governance/committees/)
 3.   Current Non-Executive Director Fees         Non-Executive Director Fees
                                                  (https://www.gsk.com/media/9371/non-executive-directors-fees.pdf)

 B.   Mr Bancroft's annual fee increased by £50,000 per annum when he became GSK's
      Senior Independent Non-Executive Director.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com/company
(https://www.gsk.com/en-gb/about-us/)

 

 GSK enquiries
 Media:               Tim Foley        +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn   +1 202 603 5003       (Washington DC)

 Investor Relations:  Nick Stone       +44 (0) 7717 618834   (London)
                      James Dodwell    +44 (0) 20 8047 2406  (London)
                      Mick Readey      +44 (0) 7990 339653   (London)
                      Josh Williams    +44 (0) 7385 415719   (London)
                      Jeff McLaughlin  +1 215 751 7002       (Philadelphia)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described in
the Company's Annual Report on Form 20-F for 2021, GSK's Q1 Results for 2022
and any impacts of the COVID-19 pandemic.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFLFLEDRIFFIF